P/E ratio for CTI BioPharma (CTIC)
P/E ratio as of April 2024 (TTM): -15.7
According to CTI BioPharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -15.6724. At the end of 2022 the company had a P/E ratio of -7.07.
P/E ratio history for CTI BioPharma from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -7.07 | 207.91% |
| 2021 | -2.30 | -47.23% |
| 2020 | -4.35 | 90.03% |
| 2019 | -2.29 | 66.25% |
| 2018 | -1.38 | -33.7% |
| 2017 | -2.08 | -7.78% |
| 2016 | -2.25 | 22.71% |
| 2015 | -1.84 | -50.99% |
| 2014 | -3.75 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 26.5 | -269.00% | 🇨🇭 Switzerland |
 Eli Lilly LLY | 134 | -951.89% | 🇺🇸 USA |
 Amgen AMGN | 19.0 | -221.47% | 🇺🇸 USA |
 Baxter BAX | 7.86 | -150.14% | 🇺🇸 USA |
 Incyte INCY | 26.9 | -271.87% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -171.84% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -6.63 | -57.73% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.